PCM
ACRS icon

Prelude Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Prelude Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,791
Closed -$18K – 983
2025
Q1 		$18K Sell
11,791
-94,560
-89% -$202K ﹤0.01% 1133
2024
Q4 		$264K Buy
+106,351
New +$265K 0.02% 858
2020
Q3 		– Sell
-375
Closed -$1K – 1765
2020
Q2 		$1K Buy
+375
New +$502 ﹤0.01% 1855

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prelude Capital Management's ACRS Position: Q2 2025 in Review

Prelude Capital Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 11,791 shares — an estimated $18K sold.

Prelude Capital Management first reported a position in ACRS in Q2 2020 and held it in 3 quarters. The position peaked at $264K in Q4 2024. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Prelude Capital Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 11,791 Aclaris Therapeutics shares in Q2 2025, an estimated $18K.
  • Prelude Capital Management first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 3 quarters.
  • Prelude Capital Management's Aclaris Therapeutics position peaked at $264K in Q4 2024.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.